Recent Articles
Page 1 of 7
August 11, 2020
Immuneering to Present at Oppenheimer’s Private Life Sciences Company Call Series
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020. Immuneering…
June 25, 2020
Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology
CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a wholly owned subsidiary…
March 25, 2020
IMMUNEERING EXPANDS ONCOLOGY SCIENTIFIC ADVISORY BOARD WITH EXPERTS IN KEY CANCER SIGNALING PATHWAY
Oncology Scientific Advisory Board to support advancement of Immuneering’s drug programs modulating the RAS/MAPK signaling pathway in cancer CAMBRIDGE, Mass. – March 25, 2020 – Immuneering Corporation today announced…
January 30, 2020
Immuneering CEO interviewed by Alex Keown of BioSpace, Inc
Published: Jan 28, 2020 By Alex Keown In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a…
January 27, 2020
WSJ Pro: Venture Capital publishes article about Immuneering Corporation
IMMUNEERING RAISES $20 MILLION FOR NEW DRUG-DISCOVERY EFFORT Company formed in 2008 also provides services to pharmaceutical companies By Brian Gormley Venture capitalists are betting $20 million that…
January 22, 2020
IMMUNEERING RAISES $20 MILLION IN OVERSUBSCRIBED SERIES A FUNDING
FINANCING TO FUND IMMUNEERING’S PIPELINE INCLUDING PROGRAMS IN CANCER CACHEXIA, NEXT-GENERATION KRAS INHIBITION AND THE RAF-MEK PATHWAY, ALL DRIVEN BY ITS DISEASE CANCELLING TECHNOLOGY CAMBRIDGE, Mass. – Jan. 22,…
January 17, 2020
The Bio Report Podcast
On this episode of The Bio Report podcast Immuneering co-founder and CEO Ben Zeskind discusses the company’s evolution from its roots in bioinformatics, movement into drug development, and the proprietary…
January 9, 2020
IMMUNEERING STRENGTHENS EXECUTIVE TEAM WITH APPOINTMENT OF HOWARD L. KAUFMAN, M.D., AS HEAD OF RESEARCH AND DEVELOPMENT
CANCER IMMUNOTHERAPY LEADER JOINS IMMUNEERING’S EXECUTIVE TEAM TO APPLY THE COMPANY’S DISEASE CANCELLING TECHNOLOGY TO IMMUNO-ONCOLOGY CAMBRIDGE, Mass. – Jan. 9, 2020 – Immuneering Corporation today announced an addition…
December 19, 2019
IMMUNEERING APPOINTS SCOTT BARRETT, M.D., AS CHIEF MEDICAL OFFICER
INDUSTRY VETERAN JOINS EXECUTIVE TEAM AS IMMUNEERING ADVANCES RAPIDLY GROWING PIPELINE OF CANCER MEDICINES DRIVEN BY DISEASE CANCELLING TECHNOLOGY CAMBRIDGE, Mass. – Dec. 19, 2019 – Immuneering Corporation today…
December 16, 2019
IMMUNEERING COMPLETES $17 MILLION SERIES A FINANCING
FUNDING TO ADVANCE RAPIDLY-GROWING PIPELINE OF CANCER MEDICINES DRIVEN BY DISEASE CANCELLING TECHNOLOGY AND EXPAND SERVICES BUSINESS CAMBRIDGE, Mass. – Dec. 16, 2019 – Immuneering Corporation today announced the…
Page 1 of 7
